Harmony Biosciences names COO Peter Anastasiou as CEO effective Jan 1 2027
Harmony Biosciences announced that its chief operating officer, Peter Anastasiou, will become president and chief executive officer on Jan. 1 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026 and serve as a non‑executive advisor in 2027. The board also reaffirmed its full‑year 2026 net‑revenue guidance for its flagship drug WAKIX at $1.0 billion to $1.04 billion. The announcement triggered a drop of about 5% in the company’s share price in early trading.
Why it matters
Investors saw the leadership change as a source of uncertainty, causing the stock to fall more than 5% in pre‑market trading. The reaffirmed revenue guidance leaves the financial outlook unchanged, but the market reaction reflects heightened caution around execution continuity.
Key facts
- 1Peter Anastasiou was appointed President, CEO and board member effective Jan. 1 2027. stocktitan.net
- 2Jeffrey M. Dayno will retire at the end of 2026 and serve as a non‑executive advisor throughout 2027. stocktitan.net
- 3Harmony reiterated its full‑year 2026 WAKIX net‑revenue guidance of $1.0 billion to $1.04 billion. investing.com
- 4Shares fell 5.2% in morning trading after the succession announcement. investing.com
- 5Shares fell 3.18% in pre‑market trading following the news. rttnews.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.